{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:05:21Z","timestamp":1761919521264},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,1,10]],"date-time":"2012-01-10T00:00:00Z","timestamp":1326153600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s00415-011-6367-4","type":"journal-article","created":{"date-parts":[[2012,1,9]],"date-time":"2012-01-09T14:09:43Z","timestamp":1326118183000},"page":"386-388","source":"Crossref","is-referenced-by-count":20,"title":["Does fingolimod in multiple sclerosis patients cause macular edema?"],"prefix":"10.1007","volume":"259","author":[{"given":"Kiran","family":"Turaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph Shepard","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,10]]},"reference":[{"key":"6367_CR1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/msj.20239","volume":"78","author":"J Derwenskus","year":"2011","unstructured":"Derwenskus J (2011) Current disease\u2014modifying treatment of multiple sclerosis. Mt Sinai J Med 78:161\u2013175","journal-title":"Mt Sinai J Med"},{"key":"6367_CR2","doi-asserted-by":"crossref","unstructured":"Huggins A, Sergott RC (2011) Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting\u2013relapsing multiple sclerosis: with special emphasis upon visual safety. Curr Opin Ophthalmol Sep 22. [Epub ahead of print]","DOI":"10.1097\/ICU.0b013e32834be03b"},{"key":"6367_CR3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1352458509357065","volume":"16","author":"G Comi","year":"2010","unstructured":"Comi G, O\u2019Connor P, Montalban X, Antel J, Radue EW, Karlsson G, Pohlmann H, Aradhye S, Kappos L, FTY720D2201 Study Group (2010) Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 16:197\u2013207","journal-title":"Mult Scler"},{"key":"6367_CR4","doi-asserted-by":"crossref","unstructured":"[No authors listed] (2009) Trial watch: Phase III promise for oral multiple sclerosis therapy Nat Rev Drug Discov 8:98","DOI":"10.1038\/nrd2821"},{"key":"6367_CR5","first-page":"213","volume":"12","author":"J Chun","year":"2011","unstructured":"Chun J, Brinkmann V (2011) A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med 12:213\u2013228","journal-title":"Discov Med"},{"key":"6367_CR6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s12325-011-0004-6","volume":"28","author":"EA Yeh","year":"2011","unstructured":"Yeh EA, Weinstock-Guttman B (2011) Fingolimod: an oral disease\u2014modifying therapy for relapsing multiple sclerosis. Adv Ther 28:270\u2013278","journal-title":"Adv Ther"},{"key":"6367_CR7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/archophthalmol.2007.23","volume":"126","author":"G Saab","year":"2008","unstructured":"Saab G, Almony A, Blinder KJ, Schuessler R, Brennan DC (2008) Reversible cystoid macular edema secondary to fingolimod in a renal transplant recipient. Arch Ophthalmol 126:140\u2013141","journal-title":"Arch Ophthalmol"},{"key":"6367_CR8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","volume":"33","author":"J Chun","year":"2010","unstructured":"Chun J, Hartung HP (2010) Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33:91\u2013101","journal-title":"Clin Neuropharmacol"},{"key":"6367_CR9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O\u2019Connor P, for the FREEDOMS Study Group (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387\u2013401","journal-title":"N Engl J Med"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-011-6367-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-011-6367-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-011-6367-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T07:28:16Z","timestamp":1561188496000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-011-6367-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,10]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["6367"],"URL":"https:\/\/doi.org\/10.1007\/s00415-011-6367-4","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,10]]}}}